Prognostic significance of serum testosterone level in patients with castration‐resistant prostate cancer treated with cabazitaxel

Background Serum testosterone level is a potential prognostic marker for castration‐resistant prostate cancer. However, its role as a prognostic marker in cabazitaxel chemotherapy remains unclear. This study aimed to elucidate the clinical significance of serum testosterone levels before cabazitaxel...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2024-01, Vol.84 (1), p.25-31
Main Authors: Fujiwara, Shinnosuke, Kosaka, Takeo, Nishimoto, Yoshinori, Kamisawa, Ken, Watanabe, Keitaro, Baba, Yuto, Takeda, Toshikazu, Matsumoto, Kazuhiro, Oya, Mototsugu
Format: Article
Language:English
Subjects:
cabazitaxel therapy
Castration
castration‐resistant prostate cancer
Chemotherapy
Medical prognosis
Metastases
Multivariate analysis
prognostic marker
Prostate cancer
serum testosterone
Survival
Testosterone
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Serum testosterone level is a potential prognostic marker for castration‐resistant prostate cancer. However, its role as a prognostic marker in cabazitaxel chemotherapy remains unclear. This study aimed to elucidate the clinical significance of serum testosterone levels before cabazitaxel chemotherapy. Methods This single‐institution, retrospective study included 47 patients with metastatic castration‐resistant prostate cancer (mCRPC) who received cabazitaxel therapy. Serum testosterone levels were measured before the initiation of cabazitaxel therapy. Results Progression‐free survival and overall survival (OS) were not significantly different between patients with high and low serum testosterone levels. Analysis of patients aged  0.055 ng/mL) had significantly longer OS than those with low serum testosterone levels (total testosterone level 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.24620